$Moderna, Inc.(MRNA)$
MRNA just surged 177% in one day after its Phase 3 personalized cancer vaccine met its key melanoma endpoints. This isn't just another early-stage biotech headline, it's a potentially major validation of Moderna's mRNA platform beyond COVID.
During the COVID era, MRNA eventually climbed all the way to an all-time closing high of $484.47.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
